CXCL9, CXCL10, and CXCL11 were chosen as targets as they represent chemoattractants for cells expressing CXCR3 which includes the majority of T cells found intrathecally in humans, and as CXCL10 is increased in the CSF of patients with MS (30–32). Here, CXCL11 is linked to myeloid sarcoma.